XML 109 R37.htm IDEA: XBRL DOCUMENT v3.20.1
SHAREHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Summary of Stock Options Granted
The following table summarizes the activities for the Company’s stock options for the year ended December 31, 2019:

   
Year ended
December 31, 2019
 
   
Number
of options
   
Weighted
average
exercise
price
   
Weighted average remaining contractual term
(in years)
   
Aggregate
intrinsic
value
 
                         
Outstanding at beginning of year
   
6,751,606
   
$
3.99
     
3.47
   
$
7,937
 
Granted
   
1,435,333
     
2.46
                 
Exercised
   
(422,311
)
   
1.42
                 
Forfeited or expired
   
(689,028
)
   
5.97
                 
                                 
Outstanding at end of the year
   
7,075,600
   
$
3.64
     
3.30
   
$
1,366
 
                                 
Options exercisable at end of the year
   
4,568,753
   
$
4.25
     
2.42
   
$
1,242
 
                                 
Vested and expected to vest
   
6,635,385
   
$
3.77
     
3.17
   
$
1,362
 
Schedule of RSUs Granted
The following table summarizes the activities for the Company’s RSUs for the year ended December 31, 2019:

   
Year ended
December 31, 2019
 
   
Number of RSUs
   
Aggregate intrinsic
value
 
             
Unvested at beginning of year
   
376,811
   
$
1,424
 
Granted
   
182,874
         
Vested
   
(152,393
)
       
Forfeited
   
(33,669
)
       
                 
Unvested at end of the year
   
373,623
     
785
 
                 
Vested and expected to vest
   
280,061
     
588
 
Summary of Stock Options And RSUs Granted Separated Into Ranges of Exercise Price
The following is a summary of the Company's stock options and RSUs granted separated into ranges of exercise price:

Exercise price
(range)
   
Options and RSUs outstanding
as of
December 31, 2019
   
Weighted
average
remaining
contractual
life (years) for outstanding options
   
Weighted
average
exercise
price
   
Options and RSUs exercisable
as of
December 31, 2019
   
Weighted
average
remaining contractual life (years) for exercisable options
   
Weighted
average
exercise
price
 
$
               
$
               
$
 
                                       
RSUs 0.0
     
373,623
     
-
     
0.00
     
-
     
-
     
0.00
 
0.01-2.00
     
1,520,110
     
1.73
     
1.21
     
1,362,569
     
1.61
     
1.20
 
2.01-4.00
     
4,159,085
     
4.31
     
2.73
     
1,905,266
     
3.45
     
2.70
 
4.01-6.00
     
325,321
     
3.62
     
4.59
     
229,834
     
2.98
     
4.75
 
6.01-8.00
     
31,000
     
2.72
     
6.50
     
31,000
     
2.72
     
6.50
 
8.01-10.00
     
459,334
     
2.19
     
8.99
     
459,334
     
2.19
     
8.99
 
10.01-13.04
     
580,750
     
0.90
     
12.40
     
580,750
     
0.90
     
12.40
 
                                                   
       
7,449,223
                     
4,568,753
                 
Schedule of Equity-Based Compensation Expense
The total equity-based compensation expense related to all of the Company's equity-based awards, recognized for the years ended December 31, 2017, 2018 and 2019, was comprised as follows:

   
Year ended
December 31,
 
   
2017
   
2018
   
2019
 
                   
Cost of revenues
 
$
54
   
$
42
   
$
71
 
Research and development
   
229
     
313
     
366
 
Selling and marketing
   
292
     
640
     
708
 
General and administrative
   
628
     
985
     
908
 
                         
Total share-based compensation expenses
 
$
1,203
   
$
1,980
   
$
2,053